InTrOducTIOn
Genetics is being increasingly used in diagnosis as well as in treatment in a wide range of areas of Reproductive Medicine. Prenatal genetic testing is a key area that is gaining popularity in many settings including Sri Lanka. This involves a multidisciplinary approach with fetal medicine and clinical genetics.
All pregnancies carry a baseline risk of 3-4% to any type of birth defect 1 
.
The severity of the anomaly may vary, reflecting the wide spectrum of mutations. Such defects can be due to inherited genetic abnormalities, de novo mutations arising in the gametes or the embryo, or effects of environmental influences that occur during pregnancy 1, 2 . Invasive prenatal testing includes the genetic evaluation of the fetus/embryo by an invasive method before birth. This requires collection of samples of placental or fetal cells, either by chorionic villous sampling (CVS) or amniocentesis, collection of exfoliated fetal cells, or direct fetal blood sampling through cordocentesis 1, 3, 4 . An increased risk, above the background risk, of fetal chromosomal aneuploidy is the most common indication for invasive prenatal testing. The contributory causes for such an increased risk calculation include the maternal age of over 35 years, a previous child with de novo chromosome abnormality, family history of detectable genetic defect, parental consanguinity in families with recessive diseases, maternal systemic illness, teratogen exposure including medication and abnormalities in amniotic fluid volume 5 .
Prenatal invasive testing poses certain procedure related risks. Spontaneous miscarriage associated with CVS and amniocentesis is estimated to be around 1-2% 2 , whereas cordocentesis is associated with an increased risk of fetal loss ranging from 1.5-2.8% 6 . A recent study suggested the risk of miscarriage with invasive testing to be much lower 7 . It is known that 1-2% of women will miscarry during early 2nd trimester, even if they have not undergone any invasive testing 7 . Therefore, it is extremely difficult to determine if a miscarriage that follows an invasive test is directly related to the procedure 7 . In clinical practice, a spontaneous miscarriage that occurs within 10 days of the invasive procedure is considered to be procedure related. The skill of the operator will influence both the success rate of the procedure as well as the procedure-related miscarriage rate8. Operators who perform a small number of procedures per year may have an failure rate and an increased rate of procedure-related pregnancy loss8. Confined placental mosaicism seen with CVS may also produce false results 2, 9 . Some authorities have recommended a minimum of 30 ultrasound guided invasive procedures per annum to maintain the competency 8 . Other indicators of quality of services include the rate of infection and maternal cell contamination.
It is recommended to carryout regular clinical audits on the outcome of invasive procedures in order to monitor and maintain the quality of care. We conducted an audit at our center assessing clinical indications, the methods of testing, and the shortterm outcome.
MeThOdS
A retrospective audit was carried out on all invasive prenatal tests done between 2013 July and 2014 July at the Fetal Medicine Unit. All the invasive procedures were done by a Fetal Medicine Foundation United Kingdom accredited operator 11 . Patient information and type of invasive procedure was obtained from the Fetal Medicine Unit database and Fetal Medicine Foundation first trimester screening software. As a good practice the outcome data is regularly collected and saved in a purpose built data sheet at this unit. The outcome data audited included results of the tests, the infection rate and procedure related miscarriage (within 10days of procedure) rate.
reSuLTS
A total of 76 patients underwent prenatal testing during the period audited (table) . This includes 13 cordocentesis procedures and 63 amniocentesis procedures (Figure 1 ). There were 10 patients who were lost to follow-up.
Screening
for common beta thalassaemia mutations was performed in five samples and four were found to be beta thalassaemia carriers for IVS I-V (G>C), IVS I-I (G>A) and CD 26 (G>A) mutations while one had a normal genotype. Therapeutic amniocentesis (amnioreduction) was performed in three (3.9%) patients for polyhydramnios. One cordocentesis was performed for flow cytometry in a woman with a positive family history of severe combined immunodeficiency disease (SCID). Vesico-amniotic shunting was done in a fetus with an obstructive uropathy. 
cOncLuSIOn:
Our data is comparable with the available international standards. We did not have procedure related miscarriages in healthy fetuses and no other procedure related complications were seen. This audit demonstrated that the procedure related complications of the unit are low among chromosomally and structurally normal fetuses after invasive prenatal testing, thus conforming acceptable safety standards 
